Adrienne Boissy, MD, MA



Similar documents
Multiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014

Growth in revenue from MS drugs has been driven largely by price increases over the last several years.

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Irene Jennifer Oh, M.D.

Medication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

JANICE MOORE SPALDING, M.D.

Clinical Trials of Disease Modifying Treatments

Which injectable medication should I take for relapsing-remitting multiple sclerosis?

L A U R A C. D R I S C O L L P T, D P T, G C S ldriscol@bu.edu

Integrating New Treatments: A Case Based Approach

KELLI DEWITT WHITEHEAD, RN, MS, ARNP

The submission positioned dimethyl fumarate as a first-line treatment option.

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents

MS Learn Online Feature Presentation Understanding MS Research Robert Lisak, MD. Tom>> And I'm Tom Kimball. Welcome to MS Learn Online.

Global Multiple Sclerosis Market: Trends and Opportunities ( )

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

Curriculum Vitae Charles E. Jeans

How to S.E.A.R.C.H. SM for the Right MS Therapy For You!

What is Multiple Sclerosis? Gener al information

PAULA JEAN PHELEY. Blacksburg, Virginia

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C Report of Foreign Private Issuer

Uncertainty in Benefit and Risk: Tysabri (natalizumab)

Department of Neurology and Neurosurgery Clinical and Clinical Research Fellowship Application Form

Case Western Reserve University Cleveland, Ohio. Masters of Science in Anesthesia Case Western Reserve University School of Medicine

Apr Dec Over 200 CME s during the past five years. Meets Ingalls Hospital and state requirements for MD s within hospital settings.

Progress in MS: Current and Emerging Therapies

Multiple Sclerosis - Relapsing and Remissioning

fingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010

Suzanne Aceron Badillo, PT, WCS

Advances in B Cell Biology:

Lemtrada (alemtuzumab)

Siri Suh 2800 Girard Ave S, #107, Minneapolis, MN Phone: (917) *

NICKOLAS LOUIS PEZZELLA, III, M.D. Physical Medicine and Rehabilitation

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy

C U R R I C U L U M V I T A E

MULTIMODAL THERAPY FOR MS- ASSOCIATED COGNITIVE DYSFUNCTION

First Name Miguel. Last Name Escalon. Institution Icahn School of Medicine at Mount Sinai. Title Assistant Professor (MD)

CURRICULUM VITAE MARK STEVEN LEMEL, M.D. Three Catherine, Sam, and Hannah

Assistant Professor Boca Raton, FL Exercise Science & Health Promotion Office: (561)

C U R R I C U L U M V I T A E

Shamil Surendra Patel, MD

LISA B. NAMEROW, M.D.

Original Policy Date

Version History. Previous Versions. for secondary progressive MS (SPMS) Policy Title. Drugs for MS.Drug facts box Interferon beta 1b

MEDICAL POLICY STATEMENT

CURRICULUM VITAE B.S. cum laude, Biology Rhodes University (prior Southwestern at Memphis) Memphis, TN

Biogen Idec Contacts: Media: Amy Brockelman (617) Investor: Eric Hoffman (617)

Kimberly D. McLaren, M.D.

JERALD H. RATNER, M.D., P.A.

Treatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD

CURRICULUM VITAE. Jane/John G. Doe, M.D., Ph.D. Associate Professor of Medicine (and include Administrative Title) Division of Cardiovascular Medicine

Performance Improvement Strategies in Multiple Sclerosis. Community of Practice Audioconference Recorded December 7, 2010

CURRICULUM VITAE. Medical Director, University Pain Medicine Center TELEPHONE NUMBER/FAX NUMBER: (732) / (732)

Gail Margoshes, Psy.D.

- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif -

Disease Modifying Therapies (DMTs) in Multiple Sclerosis

Multiple Sclerosis Drug Discoveries - What the Future Holds

Decisions relating to Multiple Sclerosis treatments

Economic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or

CURRICULUM VITAE. (b) (6) University of Oklahoma Health Sciences Center. Director of Clinical Research Unit Department of Dermaology

NHS BOURNEMOUTH AND POOLE AND NHS DORSET

Jeffrey W. Chell, M.D.

EDUCATION AND TRAINING

SHERI KAY CAREY, MS, APRN, PCNS-BC, CCRN

Pamela A. Mason, Ed.D.

Using the MS Clinical Course Descriptions in Clinical Practice

Disease Management Consensus Statement

A Career in Pediatric Hematology-Oncology? Think About It...

CURRICULUM VITAE. Veterans Administration Medical Center, Psychiatry Service San Francisco, CA Fellow in Substance Use Disorders

R ICHARD H UANG, M.D.

Natalizumab (Tysabri)

teriflunomide, 14mg, film-coated tablets (Aubagio ) SMC No. (940/14) Genzyme Ltd.

CURRICULUM VITAE PATRICK JOHN RIEDEL, M.D.

CURRICULUM VITAE. Institution Position Years in Position. The West Clinic Nurse Practitioner January 2004-present 1588 Union Avenue Memphis, TN 38104

American Academy of Pediatrics Bioethics Resident Curriculum: Case-Based Teaching Guides

Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest

Patient Group Input to CADTH

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

Personalised Medicine in MS

Transplant Program. Education REPORT

acquired chronic immune-mediated inflammatory condition of CNS. MS in children: 10% +secondary progressive MS: rare +primary progressive MS: rare

Evava S. Pietri Curriculum Vitae

Sana Louise Johnson-Quijada MD

Multiple Sclerosis (MS) Class Update

Conflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011

JOHN F. GOTTLIEB, M.D. 25 E. Washington Street Suite 1805 Chicago, IL Tel: ; FAX:

Disease Modifying Therapies for MS

How to S.E.A.R.C.H. for the Right MS Therapy for You!

Advanced Practice in MS Care

KIM EBERHARDT MUIR MS, OTR/L 3422 N LEAVITT APT 1 CHICAGO, IL KEE512@YAHOO.COM/KEBER@UIC.EDU

EDUCATION. Sarah Lawrence College B.A., Liberal Arts, 1988 POST-GRADUATE FELLOWSHIPS, GRANTS

Report to AMIA Academic Forum

Transcription:

Adrienne Boissy, MD, MA Cleveland Clinic Foundation Mellen Center for Multiple Sclerosis and Bioethics Neurological Institute Experience Officer 9500 Euclid Ave, U-10 Cleveland, Ohio 44195 Phone (216) 444-8388 Fax (216) 445-7013 boissya@ccf.org EDUCATION 1996-1997 Boston University, Graduate classes 1994-1995 Boston University, BA Biology, cum laude 1994 summer University of Maryland, College Park 1991-1994 Boston University MEDICAL EDUCATION 2006-2008 Clinical Neuroimmunology Fellowship, Cleveland Clinic Foundation 2002-2006 Neurology Residency, Cleveland Clinic Foundation 1998-2002 Pennsylvania State University Milton S Hershey College of Medicine GRADUATE EDUCATION 2007-2008 Masters Program in Bioethics, Case Western Reserve University 2006-2007 Clinical Research Scholars Program, Case Western Reserve University PROFESSIONAL APPOINTMENTS Associate Staff Cleveland Clinic, Neurological Institute, 2008-present Mellen Center for Multiple Sclerosis and Bioethics Associate Staff Patient Experience Officer, Neurological Institute 2008-present CERTIFICATION AND LICENSURE 2007-present Medical Licensure: Ohio 2007 Neurology Boards MEMBERSHIP IN PROFESSIONAL SOCIETIES 2008-present 2007-present American Society of Bioethics and Humanities AAN Ethics Section

2007-present American Society of Neuroimaging 2006-2008 Sylvia Lawry Physician Fellow, National Multiple Sclerosis Society 2005-2006 AAN-sponsored Neurology Resident Elective in Clinical Ethics, Washington DC 2002-present American Academy of Neurology PROFESSIONAL SERVICE Editorial Boards NMSS Momentum Magazine Advisory Panels 2008-present Chair, Neurological Institute Patient Advisory Panel 2009 CCF Lou Ruvo Center for Brain Health Social Services Planning Forum, Las Vegas. 2009 National Alliance for Caregivers Conference, Washington, DC. 2007 Ethics of Placebo-Controlled Trials in Multiple Sclerosis A National Multiple Sclerosis Society-sponsored Conference, Washington DC, 2007. Invited Participant/Speaker Leadership Engagement: Our Competitive Advantage, Cleveland Clinic Academy, May 2009. Overview of the Neurological Institute. CCF Embassy Event, Washington, DC, May 12, 2009. Patient Experience, CCF Connections, March 2009. COMMITTEE SERVICE Cleveland Clinic Foundation 2008-present CCF Neurological Institute Hospital Operations Committee 2008-present CCF Neurological Institute Leadership Committee 2008-present CCF Institute Experience Council 2008-present CCF NI Quality Council 2007-present CCF Subcommittee, Ethics Committee Membership 2005-present Cleveland Clinic Foundation Ethics Committee 2005-2006 CCF Subcommittee, Death by Neurological Criteria Policy Revision Cleveland Clinic Lerner College of Medicine None Educational Committees 2007-present Core Curriculum Committee for Lerner College of Medicine 2006 Curriculum Committee for Cleveland Clinic Lerner College of Medicine, Second Year Neurology and Neuroanatomy Modules 2005 Assistant Anatomy Instructor, Cleveland Clinic Lerner College of Medicine Other (institutions before CCF) 2001-2002 Admissions Committee, Pennsylvania State University College of Medicine

TEACHING ACTIVITIES: Presentations (outside lectures by invitation): June 11, 2009. Putting Patients First. Planetree Regional Patient and Family Engagement Forum. Elmhurst, IL. May 17, 2008. Understanding MS and How to Manage It for the National Multiple Sclerosis Society. May 14, 2008. Patient Experience Workshop. Ursuline College. April 17, 2008. Ethics consultations in stroke and neurological disease: seven year retrospective review AAN conference, Chicago, IL. February 14, 2008. Death by Neurological Criteria Controversies University of Wisconsin. January 19, 2008. Finding Your Way Through the White Matter ASN conference. December 7, 2007. Progressive MS for the National Multiple Sclerosis Society. November 8, 2007. Death by Neurological Criteria Controversies Case Western University. November 6, 2007. A Comparison of Japanese and American Approaches to Death by Neurological Criteria and Transplantation Case Western University. May 5, 2006. Neuroethics: Moving Beyond Finding the Lesion Citywide Bioethics Conference. April 7, 2006. Death by Neurological Criteria UNOS Region 10 Educational Forum. Teaching activities at CCF: Neurology Inpatient Service, 1-2 months per year, 2008-present Lectures: August 6, 2009. Patient Experience and You. NI Resident/Fellow Orientation Day. Cleveland, OH. June 12, 2009. Patient Experience and Wellness. Mellen Center Regional Symposium on Multiple Sclerosis. Cleveland, OH. May 21, 2009. A Touch of MS. CCF Bioethics Research Day. April 13, 2009. NI Experience Review. NI Leadership Meeting. February 24, 2009. A Complicated Relationship: MS and Bladder. CCF Urology Fellows Conference. January 16, 2009. Difficult Ethical Cases: Are There Any Other Kind? CCF Neurology Resident Lecture.

November 13, 2008. Patient Physician Communication Skills. Small Group Training Session for CCF Sleep Center. November 12, 2008. Smoothing Ruffled Feathers: Responding to the Angry, Frustrated Patient. NI Core Curriculum Series. June 3, 2008. Ethics Consultations in Neurological Disease: Learning from the Past? CCF Bioethics Grand Rounds. May 2, 2008. Over view of MS Cleveland Clinic Lerner College of Medicine. October 26, 2007. Ethics in Neurology CCF Bioethics Committee Retreat. October 3, 2007. Disease Modifying Therapy and Its Impact on Disability: The BENEFIT Trial CCF Mellen Center Journal Club. March 2007. Vitamin D and Multiple Sclerosis CCF Mellen Center Journal Club. March 2007. Optic Neuritis CCF Neurology Resident Conference. September 15, 2006, Jan 15 2007. Stroke and Ethics Cleveland Clinic Lerner College of Medicine with Dr Paul Ford. June 5, 2006. Finding Your Way through the White Matter: A Clinico-patho-radiological Conference CCF Neurology Grand Rounds. March 5, 2006. Death by Neurological Criteria or Is It? Historical Perspectives and Modern Conflicts CCF Neurology Grand Rounds. RESEARCH EXPERIENCE 1996-1998 Research Assistant, Boston University Department of Neurobiology, Boston, MA 1995-1996 Research Assistant, Brigham and Women s Hospital Department of Hematology and Oncology, Longwood, MA CLINICAL TRIAL EXPERIENCE A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind Study, to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate Injection 20 mg/ml Administered Once Daily by Subcutaneous Injection in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) TEVA PI: Dr Jeffrey Cohen 9/06-present

Role: Treating Neurologist. Also served as Principal Investigator under supervision. A Phase II, Proof of Concept, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter study to Evaluate the Safety and Efficacy of Rituximab in Adults with Relapsing Remitting Multiple Sclerosis (RRMS) Genentech, Biogen Idec, Roche PI: Dr Robert Fox 10/08-present Role: Subinvestigator A 12 Month Double Blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY-720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered IM Once Weekly in Patients with Relapsing Remitting Multiple Sclerosis with Optional Extension Phase Novartis Pharmaceuticals PI: Dr Jeffrey Cohen 2/07-present Role: Examining Neurologist Biomarkers of the Therapeutic Response to Interferon in Multiple Sclerosis PI: Dr Richard Rudick 6/06-present Role: Examining Neurologist PUBLICATIONS 1. Boissy AR. Ethical Perspectives in Neurology. Continuum Lifelong Learning in Neurology 2009. 15(4). In press. 2. Boissy AR, Edgell RC, Ford PJ, Furlan AJ. Ethics consultations in stroke and neurological disease: seven year retrospective review. Neurocritical Care 2008; 9(3): 394-399. 3. Boissy AR. Understanding the role of B-cells in multiple sclerosis: a moving target. NeuroReport 2008; 2(2):12-18. 4. Boissy AR, Cohen JC. Multiple sclerosis symptom management. Expert Rev Neurother 2007; 7(9):1213-22. Review. 5. Boissy AR, Fox RJ. Current treatment options in multiple sclerosis. Current Treatment Options in Neurology 2007; 9(3): 176-186.

6. Ford PJ, Boissy AR. Different questions, different goals. Commentary. Amer J Bioeth 2007; 7(2): 46-47. 7. Boissy AR, Ford PJ. Death by neurological criteria: continued controversies. CCF Alumni Connection 2006; 21(1): 17. 8. Boissy AR, Provencio JJ, Smith CA, Diringer MN. Neurointensivists opinions about death by neurological criteria and organ donation. Neurocritical Care 2005; 3(2): 115-121. 9. Dick AA, Lerner SM, Boissy AR, Farrell CE, Alfrey EJ. Excellent outcome in infants and small children with thrombophilias undergoing renal transplantation. Pediatr Transplantation 2005; 9(1): 39-42. 10. Alfrey EJ, Boissy AR, Lerner SA. Dual-kidney transplants: long term results. Transplantation 2003; 75(8): 1232-1236. ABSTRACTS Edgell RC, Boissy AR, Ford P, Furlan A. A seven year retrospective review of bioethics consultations in patients with stroke. Abstract. ASA international Stroke Conference, Kissimmee, Florida. February 17, 2006.